|
|||||
|
|

Semiconductor packaging and testing company Amkor Technology (NASDAQ:AMKR) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, with sales up 15.9% year on year to $1.89 billion. On top of that, next quarter’s revenue guidance ($1.65 billion at the midpoint) was surprisingly good and 7% above what analysts were expecting. Its GAAP profit of $0.69 per share was 56.8% above analysts’ consensus estimates.
Is now the time to buy AMKR? Find out in our full research report (it’s free for active Edge members).
Amkor’s fourth quarter results were met with a positive market reaction, as the company outpaced Wall Street’s expectations for both revenue and profit. Management attributed the outperformance to robust demand in advanced packaging and data center computing, as well as a surge in communications, particularly from iOS devices. CEO Kevin Engel, in his first call as chief executive, highlighted that "all end markets exceeded expectations, with the largest upside coming from communications, driven primarily by strong iOS demand." Operational improvements, notably in Vietnam’s facility and the ramp-up of advanced packaging programs, also contributed to margin expansion and strong execution in a dynamic industry environment.
Looking ahead, Amkor’s guidance reflects high expectations for continued growth in computing and advanced automotive markets, supported by accelerated investments in new capacity and technology platforms. Management views the company’s technology leadership and expanding global footprint as key enablers for 2026, with Engel stating that Amkor’s focus is on “launching new programs across advanced packaging platforms, including HDFO, flip chip, and test, which are critical to next-generation AI and high-performance computing.” CFO Megan Faust added that capital expenditures will be heavily front-loaded to support facility expansion and equipment for anticipated demand, while ongoing partnerships and customer commitments underpin the company’s outlook.
Management linked the strong Q4 results to progress in advanced packaging, improved operational execution, and strategic expansion into new markets and technologies.
Management expects future growth to be driven by continued investment in advanced packaging, customer partnerships, and geographic expansion, while closely monitoring market and policy risks.
In the coming quarters, the StockStory team will be monitoring (1) the pace and efficiency of capacity expansion in Arizona and Korea, (2) successful ramp-up and monetization of new AI and automotive packaging programs, and (3) progress in securing additional customer commitments and government incentives for ongoing investments. Execution against these milestones, as well as management’s ability to navigate supply chain and policy risks, will be key to sustaining growth.
Amkor currently trades at $54.15, up from $52.41 just before the earnings. Is there an opportunity in the stock?Find out in our full research report (it’s free).
The market’s up big this year - but there’s a catch. Just 4 stocks account for half the S&P 500’s entire gain. That kind of concentration makes investors nervous, and for good reason. While everyone piles into the same crowded names, smart investors are hunting quality where no one’s looking - and paying a fraction of the price. Check out the high-quality names we’ve flagged in our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
| Feb-17 | |
| Feb-16 | |
| Feb-14 | |
| Feb-13 | |
| Feb-12 | |
| Feb-12 | |
| Feb-12 | |
| Feb-12 | |
| Feb-11 | |
| Feb-10 | |
| Feb-10 | |
| Feb-10 | |
| Feb-10 | |
| Feb-10 | |
| Feb-10 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite